normal saline vehicle  (Intermountain Life Sciences)

Journal: ACS chemical neuroscience

Article Title: Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice

doi: 10.1021/acschemneuro.8b00013

Figure Lengend Snippet: Chemical structures of SS-31 and SS-20.

Article Snippet: Effect of Continuous SS-20 Treatment during Neuropathy Development In order to examine the effects of continuous administration of SS-20 during repeated oxaliplatin administrations, SS-20 at 5 mg/kg/day, 10 mg/kg/day or vehicle (normal saline) was continuously administered via subcutaneously implanted Alzet Micro-Osmotic Pumps (model 1004, Alzet, Cupertino, CA; pumping rate of 0.11 μ L/h for 28 days).

Techniques:

Journal: ACS chemical neuroscience

Article Title: Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice

doi: 10.1021/acschemneuro.8b00013

Figure Lengend Snippet: Effects of continuous administration of SS-20 on mechanical hypersensitivity (a) and cold hypersensitivity (b) induced by repeated administrations of oxaliplatin. Mechanical hypersensitivity was assessed by determining paw withdrawal mechanical thresholds using the von Frey hair test. Cold hypersensitivity was assessed by counting the number of forepaw-shaking behavior of mice placed on a cold plate set at 15 °C during a 2.5 min test period. Baseline measurements were made prior to the implantation of Alzet pumps filled with SS-20 at 5 mg/kg/day (n = 9), SS-20 at 10 mg/kg/day (n = 10) or vehicle (normal saline, n = 6). The Alzet pumps were implanted 2 days before the first oxaliplatin injection. Oxaliplatin (10 mg/kg) was administered intraperitoneally in mice, once per week for 3 weeks. Post-oxaliplatin measurements were made 5 days after the last administration of oxaliplatin. ##p < 0.01, ###p < 0.001 compared to the corresponding time point of the vehicle control group; *p < 0.05, **p < 0.01, ***p < 0.001 compared to baseline of the same group. Data were analyzed by two-way repeated ANOVA followed by the Bonferroni method.

Article Snippet: Effect of Continuous SS-20 Treatment during Neuropathy Development In order to examine the effects of continuous administration of SS-20 during repeated oxaliplatin administrations, SS-20 at 5 mg/kg/day, 10 mg/kg/day or vehicle (normal saline) was continuously administered via subcutaneously implanted Alzet Micro-Osmotic Pumps (model 1004, Alzet, Cupertino, CA; pumping rate of 0.11 μ L/h for 28 days).

Techniques: Injection

Journal: ACS chemical neuroscience

Article Title: Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice

doi: 10.1021/acschemneuro.8b00013

Figure Lengend Snippet: Changes in intraepidermal nerve fiber density by repeated administrations of oxaliplatin with or without concomitant SS-20 administration. Fluorescence microscopic photograph of IENFs in the planter skin harvested from a naïve mouse (a), a mouse that received three weekly administrations of oxaliplatin (10 mg/kg) with continuous administration of vehicle (normal saline) (b), and a mouse that received three weekly administrations of oxaliplatin (10 mg/kg) with continuous administration of SS-20 (10 mg/kg/day) (c). Scale bars are 50 μm.

Article Snippet: Effect of Continuous SS-20 Treatment during Neuropathy Development In order to examine the effects of continuous administration of SS-20 during repeated oxaliplatin administrations, SS-20 at 5 mg/kg/day, 10 mg/kg/day or vehicle (normal saline) was continuously administered via subcutaneously implanted Alzet Micro-Osmotic Pumps (model 1004, Alzet, Cupertino, CA; pumping rate of 0.11 μ L/h for 28 days).

Techniques: Fluorescence

Journal: ACS chemical neuroscience

Article Title: Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice

doi: 10.1021/acschemneuro.8b00013

Figure Lengend Snippet: Intraepidermal nerve fiber (IENF) densities of plantar skin (hind paw) in naïve mice (n = 4), mice given repeated administrations of oxaliplatin with continuous administration of vehicle (normal saline: NS) (oxaliplatin + NS, n = 3), and mice given repeated administrations of oxaliplatin with continuous administration of SS-20 at 10 mg/kg/day (oxaliplatin + SS-20, n = 3). Oxaliplatin at 10 mg/ kg was administered once a week for 3 weeks. IENFs counts were determined per 1 mm of epidermal border. The skin specimens were harvested 7 days after the last administration of oxaliplatin. Data were analyzed by one-way ANOVA followed by the Bonferroni method.

Article Snippet: Effect of Continuous SS-20 Treatment during Neuropathy Development In order to examine the effects of continuous administration of SS-20 during repeated oxaliplatin administrations, SS-20 at 5 mg/kg/day, 10 mg/kg/day or vehicle (normal saline) was continuously administered via subcutaneously implanted Alzet Micro-Osmotic Pumps (model 1004, Alzet, Cupertino, CA; pumping rate of 0.11 μ L/h for 28 days).

Techniques:

Journal: ACS chemical neuroscience

Article Title: Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice

doi: 10.1021/acschemneuro.8b00013

Figure Lengend Snippet: Effects of acute administration of SS-20 on mechanical hypersensitivity (a) and cold hypersensitivity (b) induced by repeated administrations of oxaliplatin. Mechanical hypersensitivity was assessed by determining paw withdrawal mechanical thresholds using the von Frey hair test. Cold hypersensitivity was assessed by counting the number of forepaw-shaking behavior of mice placed on a cold plate set at 15 °C during a 2.5 min test period (cold plate test). Baseline measurements were made prior to the first administration of oxaliplatin. Oxaliplatin (10 mg/kg) was administered intraperitoneally in mice, once per week for 3 weeks. Drug tests were performed on the 5th day after the last administration of oxaliplatin. The von Frey tests and the cold plate tests were performed before and 1 h after acute subcutaneous administration of SS-20 (10 mg/kg, n = 6) or vehicle (n = 5). **p < 0.01, ***p < 0.001 compared to baseline of the same group. Data were analyzed by two-way repeated ANOVA followed by the Bonferroni method.

Article Snippet: Effect of Continuous SS-20 Treatment during Neuropathy Development In order to examine the effects of continuous administration of SS-20 during repeated oxaliplatin administrations, SS-20 at 5 mg/kg/day, 10 mg/kg/day or vehicle (normal saline) was continuously administered via subcutaneously implanted Alzet Micro-Osmotic Pumps (model 1004, Alzet, Cupertino, CA; pumping rate of 0.11 μ L/h for 28 days).

Techniques: